Establishment Labs Holdings Inc. (NASDAQ:ESTA) Given Consensus Rating of "Moderate Buy" by Analysts

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $58.83.

A number of research analysts have recently issued reports on the company. BTIG Research lifted their price target on Establishment Labs from $62.00 to $65.00 and gave the company a "buy" rating in a report on Monday, October 14th. JPMorgan Chase & Co. cut their target price on Establishment Labs from $61.00 to $50.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 7th. Citigroup increased their price target on shares of Establishment Labs from $45.00 to $50.00 and gave the company a "neutral" rating in a research report on Tuesday, October 1st. Finally, Stephens reaffirmed an "overweight" rating and issued a $68.00 price objective on shares of Establishment Labs in a research report on Wednesday, August 7th.

Establishment Labs Stock Down 3.9 %

Establishment Labs stock traded down $1.87 during midday trading on Friday, hitting $46.25. 1,476,048 shares of the company's stock were exchanged, compared to its average volume of 379,763. The company has a debt-to-equity ratio of 4.30, a quick ratio of 2.91 and a current ratio of 4.44. The company has a market cap of $1.29 billion, a PE ratio of -15.47 and a beta of 1.20. The firm has a 50-day moving average of $43.37 and a two-hundred day moving average of $45.92. Establishment Labs has a 12 month low of $19.83 and a 12 month high of $60.12.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.11). The business had revenue of $44.12 million for the quarter, compared to the consensus estimate of $43.10 million. Establishment Labs had a negative net margin of 54.97% and a negative return on equity of 220.67%. Establishment Labs's revenue for the quarter was down 9.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.65) earnings per share. As a group, analysts expect that Establishment Labs will post -2.27 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Hood River Capital Management LLC acquired a new stake in shares of Establishment Labs during the second quarter worth about $43,000. California State Teachers Retirement System boosted its holdings in shares of Establishment Labs by 14.5% in the 1st quarter. California State Teachers Retirement System now owns 17,096 shares of the company's stock valued at $870,000 after acquiring an additional 2,167 shares during the last quarter. Swiss National Bank boosted its holdings in shares of Establishment Labs by 13.6% in the 1st quarter. Swiss National Bank now owns 37,500 shares of the company's stock valued at $1,909,000 after acquiring an additional 4,500 shares during the last quarter. Nkcfo LLC acquired a new stake in shares of Establishment Labs in the second quarter worth $227,000. Finally, Concurrent Investment Advisors LLC purchased a new position in shares of Establishment Labs during the first quarter worth $263,000. Institutional investors and hedge funds own 72.91% of the company's stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.